Multi-omics data integration to identify metabolism pathways and therapeutic targets for cardiac disease

Authors and affiliations

Sophie C. de Ruiter, MSc [1], Marion van Vugt, MSc [2, 3, 4], Chris Finan, PhD [3, 4, 5, 6], Rui Providencia, MD PhD [6, 7], Sandesh Chopade, MSc [3, 5], Diederick E. Grobbee, PhD [1], Hester M. den Ruijter, PhD [8], Sanne A.E. Peters, PhD [1, 9, *], A. Floriaan Schmidt, PhD [2, 3, 4, 5, *]

1. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
2. Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, the Netherlands
3. Institute of Cardiovascular Science, Faculty of Population Health, University College London, London, United Kingdom
4. Division Heart and Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
5. UCL British Heart Foundation Research Accelerator, London, United Kingdom
6. Health Data Research UK and Institute of Health Informatics, University College London, London, United Kingdom
7. Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom
8. Laboratory of Experimental Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
9. The George Institute for Global Health, School of Public Health, Imperial College London, London, UK

* joint senior author

Running title: Therapeutic targets and metabolic pathways for cardiac disease

Word count text: 4460

Word count abstract: 257

Number of references: 54

Number of tables and figures: 7

Number of (web) appendices: 2

Abstract

Introduction: Urinary breakdown products, representing kidney regulated filtration of metabolism end products, contain cardiac disease biomarkers such as NT-proBNP. We set out to integrate plasma proteins with metabolism pathways, as reflected by urinary breakdown products, to identify potentially druggable metabolism pathways for cardiac disease.

Methods: Data was leveraged from a genome-wide association study (GWAS) on 954 urinary breakdown products. Mendelian randomisation was used to identify urinary breakdown products associating with atrial fibrillation (AF), heart failure (HF), dilated cardiomyopathy (DCM), or hypertrophic cardiomyopathy (HCM). By interrogating eight independent plasma protein GWAS, jointly including 92,277 participants and 1,562 unique proteins, we identified druggable plasma proteins with a directionally concordant effect on urinary breakdown products and cardiac outcomes.

Results: In total, 38 unique urinary breakdown products associated with cardiac disease, predominantly covering breakdown products from amino acid metabolism (n=12), xenobiotic metabolism (n=5), and unclassified metabolism origins (n=16). Subsequently, we identified 32 druggable proteins expressed in cardiac tissue, which had a directionally concordant association with the identified urinary breakdown products and cardiac outcomes. This included positive control findings, for example higher values of AT1B2 (targeted by digoxin) decreased the risk of HCM, which we were able to link to a novel unclassified urinary breakdown product (X-15497). Additionally, we showed that increased plasma RET values, a mediator of GDF-15 signalling, reduced the risk of HF, and linked this to the novel unclassified urinary breakdown product X-23776.

Conclusion: We have identified amino acid, xenobiotic and unclassified metabolism as important pathways contributing to cardiac disease and prioritised 32 druggable proteins as potential therapeutic targets.

Introduction

Heart failure (HF) and atrial fibrillation (AF) are cardiac diseases which manifest as ventricular and atrial dysfunction, respectively. While AF frequently affects people without established HF, in people with HF an AF diagnosis often signals early progressive HF, where ventricular disfunction has an early knock-on effect on atrial rhythm and output. People with hypertrophic cardiomyopathies (HCM), a subtype of HF characterized by an abnormally large and stiff cardiac septum, which may limit cardiac output and affect diastolic function, are particularly susceptible to develop AF. Aside from HCM, dilated cardiomyopathy (DCM) represents a second major non-ischemic HF subtype, where the left ventricle becomes enlarged and thin, limiting cardiac contractility. As such, AF and HF are closely interrelated diseases, with specific underlying pathologies like HCM and DCM playing distinct roles in their manifestation.

Aside from N-terminal prohormone of brain natriuretic peptide (NT-proBNP), which associates with HF and AF progression(1-3), there is paucity of biomarkers to assist medical practitioners in tailored treatment management, diagnosis, and prognosis. NT-proBNP, which is secreted by cardiomyocytes (cardiac cells responsible for contraction), can be measured in both blood plasma and urine, illustrating the interface between cardiac tissue processes, blood, and urine. Urine biomarkers provide a non-invasive measurement of potential causal metabolic changes reflecting disease onset and progression. While urinary breakdown products represent by-products cleared from plasma, the source of these breakdown products may reflect pathophysiological changes in tissues such as the cardiac muscle. Cardiac function and kidney function are intertwined, through for example the renin-angiotensin-aldosterone system, and the concept of cardiorenal syndrome has been implemented to describe disorders involving both organs, with dysfunction in one organ causing acute or chronic dysfunction in the other(4, 5). Urinary breakdown products are therefore a potentially important source of non-invasive disease markers, which may unveil upstream involvement of biological pathways relevant for cardiac progression and/or novel cardiac therapeutics.

Recently, availability of affordable, high-throughput assays capable of measuring hundreds of proteins and metabolites has facilitated their analysis in large sample size genome wide association studies (GWAS). Given that proteins form the main constituents of drug targets, GWAS on protein values provide an invaluable resource to identify potential drug targets through genomics tools such as Mendelian randomisation (MR). Utilizing MR, one can infer the effect of an exposure (e.g. a breakdown product or protein) on the risk of disease, by identifying genetic variants strongly associated with the exposure, and determining whether there is a dose-response relationship between the genetic associations with the exposure and the genetic associations with disease(6, 7). Given that genetic variants are fixed at gametogenesis, genetic evidence is robust against bias due to confounding or reverse causation(8, 9). These principles have been extensively validated in the context of cardiovascular disease(10-13), including in a recent study on the effects of plasma proteins on cardiac function and structure(14).

Although urinary breakdown products are important markers of potential disease mechanisms, they are not directly actionable because they have already been excreted. Plasma proteins are however still actionable and are the main constituents of drug targets. Therefore, we integrated information from urinary metabolism breakdown products to identify metabolism pathways relevant for cardiac disease and information from plasma proteins to identify drug targets that may be used to intervene in these pathways.

In the current manuscript we used MR to analyse urinary metabolism breakdown products to identify metabolism pathways with possible involvement with four cardiac disease traits: AF, HF, DCM, and HCM. Subsequently, we sought to establish potential plasma protein intermediates by identifying proteins associating with urinary breakdown product values, as well as with cardiac disease risk. The Human Protein Atlas (HPA) was consulted to identify proteins expressed in cardiac tissue, providing further support for cardiac involvement. The subset of proteins expressed in cardiac tissue were subsequently mapped to biological pathways, with druggability determined through linkage with ChEMBL.

Methods

Available data

We used a GWAS on 954 urinary breakdown products, which were identified and quantified among 1,627 individuals using a non-targeted mass spectrometry assay provided by Metabolon(15). This untargeted approach allows for comprehensive detection of breakdown products, including those of unknown origin. Breakdown products were categorised based on the metabolic origin of the urinary breakdown products: amino acids, carbohydrates, cofactors and vitamins, energy, lipids, nucleotides, peptides, xenobiotics, and unclassified. Xenobiotic breakdown products - substances not naturally produced by the human body, include breakdown products from drugs, environmental pollutants, and various synthetic compounds. Unclassified breakdown products represent potentially novel biomarkers, as they have not yet been related to an established metabolic origin. These breakdown products were noted for their recurring chromatographic and spectral properties and have been assigned unique COMP-IDs and/or CHEM-IDs (**Supplementary Table S1**), which allows for identification and comparison in future studies and by other analysis platforms. Genetic associations with plasma protein values were available from the eight GWAS, detailed in Supplementary Note 1. Genetic associations with cardiac disease onset were available from Nielsen *et al.* (60,620 AF cases)(16), from Shah *et al.* (47,309 HF cases)(17), from Garnier *et al*. (2,719 DCM cases)(18), and from Zhou *et al.* (2,993 HCM cases)(19). Study specific participants characteristics and case/control definitions are described in Supplementary Note 1. All studies obtained informed consent from participants and complied with the Declaration of Helsinki.

Mendelian randomisation analyses

Three MR analyses were conducted: 1) genome-wide MR identifying metabolism pathways which, as reflected by urinary breakdown products, associate with onset of cardiac disease (step 1 **Figure 1, Appendix Tables S1, S2**), 2) *cis*-MR identifying plasma proteins affecting values of urinary breakdown products (step 2 **Figure 1**), and 3) *cis*-MR identifying plasma proteins which associate

with the onset of cardiac disease (step 3 **Figure 1**). In the genome-wide MR we selected genetic variants from across the genome, while in the *cis*-MR genetic variants were selected from a 200 kilobase pair window around and within the protein encoding gene. In both cases, variants were selected based on an exposure F-statistic of at least 24 and a minor allele frequency of 0.01 or larger. The remaining variants were clumped to a linkage disequilibrium (LD) r-squared of 0.30, based on a random 5,000 sample of unrelated UK Biobank participants. The *cis*-MR analyses (steps 2-3 **Figure 1)** were conducted per individual protein GWAS, where the largest sample size GWAS was used in the case of overlap in measured proteins.

MR analyses were conducted using generalized least squares (GLS) implementations of the inverse variance weighted (IVW) estimator, as well as the pleiotropy robust MR-Egger estimator(20). The GLS implementation was used to additionally correct for residual LD, which optimized estimator precision(21). To reduce the potential for horizontal pleiotropy, we excluded variants with large leverage statistics (larger than three times the mean leverage) and/or outlier statistics (Chi-square larger than 10.83). Analyses with fewer than 6 variants as instrument were discarded to ensure we had sufficient data to accurately model the exposure effects. The potential influence of horizontal pleiotropy was further minimized by applying a model selection framework identifying the MR model (IVW or MR-Egger) most supported by the available data (Supplementary Note 1).

Effect estimates and multiple testing

MR results are presented as mean differences (MD) for continuous outcomes, or odds ratios (ORs) for binary outcomes, representing the effect of an SD increase of the exposure (i.e., either urinary breakdown product or plasma protein value). Effect estimates are not constrained to be positive (i.e., they can indicate an increase or decrease in the outcome) and are accompanied by 95% confidence intervals (CIs) and p-values. Breakdown product effects on disease were filtered for a multiplicity corrected p-value threshold of $1.37\times10^{\square\square}$ based on the 365 principal components that were needed to explain 90% of the urinary breakdown product variance (**Appendix Figure S1**). Protein MR effect estimates were evaluated against a multiplicity corrected p-value of 8.42×10^{-7} for the breakdown

products, based on the number of tested proteins (n=1,562) and breakdown products (n=38). The multiplicity corrected p-value was 1.76×10^{-5} for cardiac outcomes, based on the number of tested proteins (n=709) and outcomes (n=4). Proteins are referred to using their Uniprot label(22), while genes are referred to using their Ensembl label in italicised font.

Triangulation of evidence through consideration of concordant cardiac effects

The three distinct MR analyses were integrated by I) identifying urinary breakdown products affecting cardiac disease, II) identifying whether there were proteins associated with these urinary breakdown products, and III) focussing on the subset of proteins with a directionally concordant effect on the same cardiac disease trait the urinary breakdown products associated with. For example, if a higher value of a urinary breakdown product decreased the risk of HF, and the protein increased the urinary breakdown product value, the protein effect was considered directionally concordant if in turn higher protein values decreased HF risk. Conversely, if a higher value of a urinary breakdown product increased the risk of HF, and the protein decreased the urinary breakdown product value, the protein effect would still be considered directionally concordant if higher protein values decreased HF risk. When all these conditions are met – directional concordance between the protein, breakdown product, and cardiac outcome – we describe this as a triangulated association (**Figure 2**). We note that because each performed MR analysis makes a distinct, and independent, assumption on the absence of horizontal pleiotropy, focusing on the directionally concordant results is anticipated to identify a robust subset of analyses with limited influence of potential horizontal pleiotropy.

Prioritisation of proteins expressed in cardiac tissue

The set of proteins with a triangulated effect on breakdown product and cardiac outcome were subsequently prioritised for the presence of cardiac tissue mRNA expression, differentiating between proteins with general cardiac expression, and proteins which were overexpressed (Supplementary Note 1). We also tested for overexpression in other tissues, providing greater context regarding the type of protein.

Annotation of prioritised proteins

We identified plasma proteins targeted by approved drugs (drugged proteins), as well as potentially druggable proteins based on ChEMBL-v33. For the drugged and druggable proteins, we additionally extracted compound indications and side-effects, sourcing information from ChEMBL and the British National Formulary (BNF, access date September 4, 2021). Finally, all proteins available in the considered GWAS were mapped to biological pathways using the Reactome knowledgebase-v85(23) and prioritised proteins (combined irrespective of cardiac or metabolite class association, as well as, stratified by cardiac disease, or stratified by metabolite class) were tested for enrichment against the full set of 1,567 proteins.

Partial replication of protein associations with cardiac traits

Due to the availability of 8 proteomics GWAS, some studies assayed the same proteins, which we leveraged to replicate our findings, specifically focussing on associations with cardiac traits. Replication was sought using a nominally significant p-value of 0.05 or smaller and considering the effect direction of the triangulated analysis. In addition, a more stringent p-value threshold of 8.93×10^{-4} (0.05 divided by the number of proteins available in more than one study) was used for more conservative replication.

Results

Urinary breakdown products associating with the onset of cardiac disease

We conducted Mendelian randomisation to identify urinary breakdown products linked to cardiac disease, unveiling potential non-invasive biomarkers and altered metabolism pathways involved in cardiac disease progression. Out of 954 evaluated urinary breakdown products (**Appendix Table S1**), 38 breakdown products were found to be associated with at least one type of cardiac disease: 25 for AF, 11 for HF, 5 for DCM, and 14 for HCM (step 1 **Figure 1**, **Appendix Tables S2, S3, Figure 3**). Urinary breakdown products were frequently associated with AF, where particularly amino acid and xenobiotic breakdown products associated with cardiac diseases. For example, higher values of 1-

methylhistamine increased the risk of HF (OR 1.07, 95%CI 1.05; 1.09), while decreasing the risk of AF (OR 0.83, 95%CI 0.76; 0.90). Higher values of 1-methylxanthine, a xenobiotic breakdown product of caffeine, decreased the risk of AF, DCM, and HCM (**Appendix Table S2, Figure 3)**. Finally, we were able to associate 16 urinary breakdown products of unknown metabolic origin (unclassified breakdown products) with cardiac disease.

Triangulated proteins with concordant effects on urinary breakdown products and cardiac diseases

Mendelian randomisation was used to determine associations between plasma proteins and the 38 urinary breakdown products associated with cardiac disease. We identified 709 proteins associated with at least one of the 38 urinary breakdown products (step 2 **Figure 1, Appendix Figure S2**). We then used MR to identify which of these proteins also associated with the considered cardiac diseases and identified 235 proteins (step 3 **Figure 1, Appendix Figure S3**). By considering directional concordance and cardiac tissue expression we identified 91 prioritised proteins (step 4 **Figure 1, Appendix Tables S4, S5)**.

This prioritised set included 6 proteins which were overexpressed in cardiac tissues on mRNA level (**Figure 4**): TIG1 (affecting urinary breakdown products 1-methylxanthine), DNJA4 (affecting urinary breakdown product X-19141), NAR3 (affecting urinary breakdown products n-acetylcitrulline, 4-guanidinobutanoate, and X-23776), SPT20 (affecting urinary breakdown products 1-methylhistamine and X-19141), GLO2 (affecting urinary breakdown products n-methylpipecolate and 3-hydroxyindolin-2-one sulfate), and PLXA1 (affecting urinary breakdown products 1-methylhistamine, glycocholenate sulfate, and 1-methylxanthine) (**Appendix Table S4**). Besides their overexpression in cardiac tissue, these proteins were also overexpressed in at least one other tissue in the body, such as the skeletal muscle and ovaries (**Appendix Table S4**).

Drugged and druggable prioritised proteins

We sourced ChEMBL and BNF to determine druggability of the prioritised proteins. The set of 91 prioritised proteins included 20 drugged proteins, and 12 druggable proteins (step 4 **Figure 1)**. The 20 drugged proteins included seven positive control proteins where the drug indication matched the MR disease association (ACES, EGLN1, ICAM1, NQO2, RET, TRY3, and UD11). For example, we showed that higher levels of ACES increased the risk of both AF and HF, mimicking the protective effect of ACE inhibitor drugs. Furthermore, we identified six proteins targeted by a drug indicated for a cardiac disease distinct from the MR associations (MANBA, NQO1, NTRK3, OLA1, TEC, and TRYB1), identifying compounds relevant for rapid drug repositioning. For example, MANBA is targeted by migalastat used to treat GLA amenable Fabry disease, where the MR analysis supported potential repositioning to treat AF. Additionally, we identified three proteins (AT1B2, DPEP1, and MET) targeted by drug compounds with a registered cardiac side-effect which may be relevant for drug repurposing. Finally, four proteins were targeted by drug compounds without a cardiac indication or side effect, providing further opportunities for drug repurposing. For example, ADH1B (associated with HF) is targeted by nitrefazole which is used to treat alcohol addiction (**Table 1, Figure 5, Appendix Tables S7, S8**).

Irrespective of the known side effects or indications, the identified proteins frequently associated with AF, with many of these proteins (partially) acting through xenobiotic (n=8) and amino acid (n=6) metabolism (**Figure 5**). Specifically, GLO2, ACES, EGLN1 (OR 0.88, 95% CI 0.84; 0.92), LYAM2, IBP3, and ENTP5 affected AF and associated with xenobiotic breakdown product values. Similarly, DPEP1 (OR 0.97, 95% CI 0.96; 0.98), TRYB1, HEXI1, and TEC (OR 0.87, 95% CI 0.83; 0.90) affected AF and associated with amino acid breakdown product values. Higher values of TRY3 (OR 0.92, 95% CI 0.90; 0.94) and NAGK decreased AF risk and associated with both amino acid and xenobiotic breakdown products values.

Most proteins affecting HF associated with unclassified metabolism pathways (n=7). Specifically, increased values of ACES, RET (OR 0.97, 95% CI 0.96; 0.98), ADH1B, ERAP1 (OR 0.97, 95% CI

0.96; 0.98), FCG2A, NQO1, and CTGF affected HF risk and also associated with unclassified urinary breakdown products.

Similarly, drugged and druggable proteins affecting HCM predominantly associated with unclassified metabolism pathways (n=5). Specifically, higher values of ICAM1, NTRK3, CAN2, SIGL7, and AT1B2 affected HCM risk.

For DCM we identified three drugged or druggable proteins with higher values of UD11 and CATA increasing DCM risk and associating with peptide breakdown product prolylglycine, and higher values of PLA2R (OR 0.92, 95% CI 0.91; 0.94) decreasing DCM risk and associating with xenobiotic breakdown product N-methylpipecolate.

Triangulated proteins with an effect on multiple cardiac traits

We additionally identified eleven pleiotropic proteins associated with multiple cardiac outcomes. Most of these were associated with unclassified and xenobiotic urinary metabolism breakdown products. Specifically, ACES, PLXB2, PLXA1, CYTF, and GNPTG affected AF and HF (**Figure 6**). ICAM1, MICB, and EVA1C affected both HCM and HF, while MATN3 and ACYP2 affected HCM and AF, while PLA2R affected HCM and DCM (**Figure 6, Appendix Table S6**).

Proteins enriched in biological pathways

Based on the Reactome knowledgebase, we found the “antigen presentation: folding, assembly and peptide loading of class I MHC” pathway to be enriched among the triangulated proteins. This pathway involved proteins TPSN (associated with HCM) and ERAP1 (associated with HF) (**Appendix Tables S6, S9**). Enriched pathways in the subset of prioritised proteins per metabolite class and per disease outcome are indicated in **Appendix Figure S4** and **S5**.

Replication of protein effects on cardiac outcomes

Of the 91 prioritised proteins associating with one or more cardiac traits 56 were available in more than a single study, applying a nominal 0.05 p-value threshold this resulted in a replication of 47 (84%) protein associations with cardiac disease. Applying a multiplicity corrected threshold resulted in 37 (66%) replicated proteins (**Appendix Table S10**). Replication results for protein effects on breakdown product values are described in Supplementary Note 1 (**Appendix Table S11**).

Discussion

In this study, we used Mendelian randomisation to assess relationships between 954 urinary breakdown products, 1,562 proteins, and four cardiac diseases AF, HF, DCM, and HCM. We found directionally concordant associations between 38 breakdown products, 91 cardiac expressed proteins, and the considered cardiac diseases. The urinary breakdown products are potential biomarkers of altered metabolism pathways informative of the aetiology and consequences of cardiac diseases, and the plasma proteins may be used as drug targets to intervene in these metabolism pathways.

The identified urinary breakdown products associating with cardiac disease predominantly included breakdown products with an origin in amino acids metabolism, xenobiotics metabolism, and of unclassified metabolism. Of the 91 proteins, six were overexpressed in cardiac tissue. We additionally identified eleven pleiotropic proteins with an effect on more than one cardiac outcome. Furthermore, 20 proteins were targeted by an approved drug, which included seven positive control proteins that were targeted by a compound with a cardiac indication matching the MR disease association (ACES, EGLN1, ICAM1, NQO2, RET, TRY3, and UD11), as well as six targets for drugs with a cardiac indication distinct from the MR disease association (MANBA, NQO1, NTRK3, OLA1, TEC, and TRYB1), and three targets for drugs with a known cardiovascular side-effect (AT1B2, DPEP1, and MET) which may be relevant for drug repurposing. For example, we found that the approved compounds nitrefazole and arginine may be beneficially repurposed to treat HF or AF, respectively. Future studies may consider analysis of available (nationwide) prescription data to provide further evidence of efficacy, which may be confirmed by more time consuming and costly randomised controlled trials.

We identified seven amino acids breakdown products associated with AF of which six (cysteinylglycine disulfide, 4-guanidinobutanoate, N-acetylcitrulline, N-acetyl-3-methylhistidine, N-acetylarginine, and N-acetylasparagine) increased the risk of AF, corroborating previous observations of altered amino acid metabolism in AF patients(24). We found 27 proteins associated with these amino acids and AF, including 7 drugged or druggable proteins. For example, we showed that higher values of MANBA (mannosidase beta) increased AF risk, which is supported by recent GWAS associating genetic variants near *MANBA* with AF(25) and by two recent MR studies identifying MANBA as a potential drug target for AF with corresponding effect directions(26, 27). MANBA is targeted by migalastat, a drug used to treat Fabry disease(28), which closely resembles HCM(29), with patients often suffering from cardiac arrhythmias and conduction tissue infiltration, leading to electrical instabilities. An observational study on Fabry disease patients revealed that atrial function was better preserved in those treated with migalastat compared to untreated individuals(30). Through our analyses of urinary breakdown products, we were able to link MANBA to fatty acid metabolism through nonenedioate, with faulty fat metabolism a canonical characteristic of Fabry disease(31). Jointly, this suggest MANBA may offer therapeutic potential for treatment of AF and related arrythmias through altered lipid metabolism. These insights not only improve our understanding of the metabolic origins of atrial fibrillation but also highlight MANBA as a promising target for intervention. The potential to repurpose migalastat or develop new therapies targeting MANBA offers a novel approach for AF treatment, potentially relevant in patients with metabolic disturbances similar to those observed in Fabry disease. Additionally, we found that higher levels of MET are associated with reduced AF risk. MET is targeted by crizotinib, a cancer drug which has side-effects including arrythmias. Previous research also identified MET as target with repurposing potential for AF treatment(32).

We identified eleven urinary breakdown products associating with HF which included five breakdown products with an origin in amino acids metabolism and five with an unclassified origin. We were able to map these to 27 plasma proteins with a directionally concordant HF effect, which included MICB

(MHC class I polypeptide-related sequence B). MICB increased the risk of both HF and HCM, and was linked to seven yet unclassified breakdown products. This closely aligns with our pathway enrichment analysis identifying MHC class I related pathways implicated in HCM (based on protein TPSN) and HF (based on protein ERAP1), which are linked to CD8+ T-cell mediated cardiac remodelling(33), underscoring the potential role of immune modulation in the pathogenesis of these conditions. While these proteins are not yet druggable, our analysis did identify ICAM1 (associating with HCM and HF), RET and NQO2 (both associating with HF), which have already been drugged. Through consideration of urinary breakdown products we were able to associate ICAM1 with 1-methylxanthine and X-18889, where the former is a breakdown product of xanthine, and the oxidation of xanthine has been linked to ICAM1 neutrophil binding capacity(34). Notably, immune cell activation, reflecting systemic but low-grade inflammation, is a likely key pathophysiologic process progressing towards HCM, other cardiomyopathies, and end-stage HF(35). Regorafenib, a RET inhibiting drug that is used for cancer treatment, has registered side effects including myocardial ischemia and hypertension. These side effects support our findings that lower values of RET are associated with a higher risk of HF onset, where the unclassified urinary breakdown product X-23776 was involved in the triangulated association. The GDNF family receptor α–like (GFRAL) acts a receptor for GDF15, which signals through the RET co-receptor. GDF15 was found to be relevant for energy homeostasis and has been identified as a biomarker of cardiovascular and metabolic diseases. There is potential for a new class of drugs based on GDF15-GFRAL-RET, where the signalling pathway is modified(36). Additionally, GDF15 has been recognized as an indicator for HF risk and prediction of hospitalisation for HF or all-cause mortality before(37). The protein NQO2 was associated with a decreased risk of HF, through the amino acid breakdown product indoleacetylglutamine. Prazosin, which acts as an adrenergic receptor alpha-1 antagonist and targets NQO2, has shown potential benefits for HF patients in previous observational studies and trials(38, 39), suggesting prazosin might be a relevant repurposing candidate for HF.

We found five urinary breakdown products and eight proteins associated with DCM risk, including three drugged or druggable proteins, underscoring their potential clinical relevance. For example, we

showed that increased values of UD11 increased the risk for DCM and reduced the values of the peptide breakdown product prolylglycine. UD11 is targeted by beta-blockers carvedilol and labetalol (used for HF, hypertension, coronary artery disease and myocardial ischemia), by the diuretics furosemide and bumetanide (used for HF and hypertension) and by acetazolamide, which is not used in practice but has shown benefits in acute decompensated heart failure in a previous clinical trial(40). These findings suggest that modulation of UD11 could be a viable therapeutic strategy in reducing the risk of DCM, providing a rationale for further investigation of UD11 as drug target for treatment for individuals at risk of DCM.

We note that 13 prioritised proteins affected xenobiotic urinary breakdown product values, indicating that these proteins affect xenobiotic metabolism and excretion. For example, we found that ICAM1 associates with the urinary breakdown product value of xenobiotic 1-methylxanthine. This is in line with previous findings indicating that increased expression of ICAM1, which is present on the leukocytes (as well as endothelial cells), facilitates phagocytosis of xenobiotics(41-43).

Despite the robustness of combining multiple MR analyses sourcing various GWAS on both proteins and breakdown products, there are some potential limitations that we wish to discuss. First of all, the genetic data we used was sourced from multiple GWAS which used various high throughput assays, varying in accuracy and analytic scope(44). Instead of directly measuring concentrations, these assays evaluate relative values of proteins or breakdown products. Hence, the magnitude of association is difficult to interpret, and potential follow-up studies are needed to explore compound specific pharmacokinetic and pharmacodynamic properties. Our current analysis predominantly provides information on the putative drug mechanism and whether compounds should be inhibitory or activating. In addition, associations between urinary breakdown products and cardiac disease should not be misinterpreted as implying that urinary breakdown products themselves have a causal effect on disease. Rather we use urinary breakdown products as a proxy for more distal metabolic processes, such as those occurring in or impacting cardiac tissue. Due to relying on aggregate data instead of individual patient data, we could not explore potential influence of variant by environment

interactions, for example due to differences in sex or fasting state. However, genetic variants are determined at gametogenesis and therefore MR is protected against most forms of confounding reflecting the presence of a common cause of the genetic variant and the outcome or exposure. Even in the presence of variant by environment interaction, our triangulation approach prioritises results where these interactions are either absent or of minimal importance. This makes our approach conservative, potentially overlooking a number of true associations, but the associations we do identify are robust against environmental influences, which is also indicated by the high degree of replication. Furthermore, GWAS data were mainly obtained from European cohorts, which may limit generalizability to non-European populations. Finally, while we had access to a large sample size GWAS on HF (47,309 cases), we did not have information on HF subtypes, and future studies considering HF subtypes may yield additional insights.

Examining the associations between urinary breakdown products, cardiac disease and proteins in a triangulated way provides a comprehensive and robust analysis. Concordance in results from all three analyses – which are based on distinct sources of data – indicate a more reliable effect. Discordant results however do not necessarily indicate invalid MRs but are potentially indicative of a limited influence of the protein on the metabolism process influencing cardiac disease, or may reflect more intricate biological processes.

In conclusion, 38 metabolism pathways and 91 proteins were identified for involvement with cardiac disease, providing important evidence to support drug development of novel and repurposing targets. Additionally, our manuscript illustrates the value of integrating multi-modal sources of evidence to identify information potentially relevant for disease diagnosis, prognosis, and aetiology.

Funding: SD and SAEP are supported by a VIDI Fellowship (project number 09150172010050) from the Dutch Organisation for Health Research and Development (ZonMW) awarded to SAEP. AFS is supported by BHF grant PG/22/10989, the UCL BHF Research Accelerator AA/18/6/34223, MR/V033867/1, the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the EU Horizon scheme (AI4HF 101080430 and DataTools4Heart 101057849). This work was supported by the NWO Snellius supercomputer project (application 2023.022).

Role of funders: The funding source did not influence the study design, the collection, analysis, and interpretation of data, the writing of the report, or the decision to submit the manuscript for publication.

Acknowledgements: A preprint version of this manuscript has been deposited at: https://doi.org/10.1101/2024.02.27.24303421. This research has been conducted using the UK Biobank Resource under Application Number 12113. The authors are grateful to UK Biobank participants.

Declaration of competing interests: AFS and CF have received funding from New Amsterdam Pharma for unrelated projects. The other authors declare that they have no conflict of interest.

Author contributions: SD, AFS, and SP designed the study. SD and MV accessed the data, verified the data, and performed analyses. SD drafted the manuscript. All authors provided critical input on the analysis, as well as the drafted manuscript.

Code availability: Analyses were conducted using Python v3.7.13 (for GNU Linux), Pandas v1.3.5, Numpy v1.21.6, bio-misc v0.1.4, and matplotlib v3.4.3. Code to reproduce figures and tables will be made available upon publication. Genetic summary-level data underpinning each individual MR analysis will be made available at Figshare upon publication.

Data availability: The individual GWAS data on cardiac outcomes leveraged in this study can be accessed as follows: atrial fibrillation (cases=60,620, total n=1,030,836; https://www.ebi.ac.uk/gwas/publications/30061737), heart failure (cases=47,309, total n=977,323; https://www.ebi.ac.uk/gwas/publications/31919418), dilated cardiomyopathy (cases=2,719, total n=6,980; https://www.ebi.ac.uk/gwas/publications/33677556) and hypertrophic cardiomyopathy (cases=2,993, total n=1,197,200; http://results.globalbiobankmeta.org/pheno/HCM). The GWAS data on urinary breakdown product values can be accessed via https://www.ebi.ac.uk/gwas/publications/31959995 (n=1,627). The individual GWAS data on plasma protein values can be accessed as follows: deCODE (n=35,559, https://www.decode.com/summarydata/), SCALLOP (n=30,931, https://www.ebi.ac.uk/gwas/publications/33067605), Ahola-Olli et al. (n=8,293, https://www.ebi.ac.uk/gwas/publications/27989323), Framingham (n=6,861, https://www.ebi.ac.uk/gwas/publications/21909115), AGES-Reykjavik (n=5,368, https://www.ebi.ac.uk/gwas/publications/35078996), INTERVAL (n=3,301, https://www.ebi.ac.uk/gwas/publications/29875488), Gilly et al. (n=1,328, https://www.ebi.ac.uk/gwas/publications/33303764), and Yang et al. (n=636, https://www.ebi.ac.uk/gwas/publications/34239129).

References

1. Cortés R, Portolés M, Salvador A, Bertomeu V, de Burgos FG, Martínez□Dolz L, Lletí ER, Climent V, Jordán A, Payá R. Diagnostic and prognostic value of urine NT□proBNP levels in heart failure patients. European journal of heart failure. 2006;8(6):621-7.
2. Panagopoulou V, Deftereos S, Kossyvakis C, Raisakis K, Giannopoulos G, Bouras G, Pyrgakis V, W Cleman M. NTproBNP: an important biomarker in cardiac diseases. Current topics in medicinal chemistry. 2013;13(2):82-94.
3. Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. International journal of molecular sciences. 2019;20(8):1820.
4. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. Journal of managed care pharmacy. 2007;13(8 Supp B):9-20.
5. Rangaswami J, Bhalla V, Blair JE, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K, Molitch M, Mullens W. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840-e78.
6. Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, Tyl B, Chopade S, Faraway R, Zwierzyna M. Genetic drug target validation using Mendelian randomisation. Nature communications. 2020;11(1):1-12.
7. Schmidt AF, Hingorani AD, Finan C. Human Genomics and Drug Development. Cold Spring Harb Perspect Med. 2022;12(2).
8. Hingorani A, Humphries S. Nature's randomised trials. The Lancet. 2005;366(9501):1906-8.
9. de Ruiter SC, Schmidt AF, Grobbee DE, den Ruijter HM, Peters SA. Sex-specific Mendelian randomisation to assess the causality of sex differences in the effects of risk factors and treatment: Spotlight on hypertension. Journal of Human Hypertension. 2023:1-7.
10. Cupido AJ, Asselbergs FW, Natarajan P, Group CIW, Ridker PM, Hovingh GK, Schmidt AF. Dissecting the IL□6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R. British Journal of Clinical Pharmacology. 2022;88(6):2875-84.
11. Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nature genetics. 2020;52(10):1122-31.
12. Schmidt AF, Hunt NB, Gordillo-Marañón M, Charoen P, Drenos F, Kivimaki M, Lawlor DA, Giambartolomei C, Papacosta O, Chaturvedi N. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nature communications. 2021;12(1):5640.
13. Consortium I-RMRA. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. The Lancet. 2012;379(9822):1214-24.
14. Schmidt AF, Bourfiss M, Alasiri A, Puyol-Anton E, Chopade S, van Vugt M, van der Laan SW, Gross C, Clarkson C, Henry A. Druggable proteins influencing cardiac structure and function: Implications for heart failure therapies and cancer cardiotoxicity. Science Advances. 2023;9(17):eadd4984.
15. Schlosser P, Li Y, Sekula P, Raffler J, Grundner-Culemann F, Pietzner M, Cheng Y, Wuttke M, Steinbrenner I, Schultheiss UT. Genetic studies of urinary metabolites illuminate mechanisms of detoxification and excretion in humans. Nature genetics. 2020;52(2):167-76.
16. Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, Herron TJ, McCarthy S, Schmidt EM, Sveinbjornsson G. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nature genetics. 2018;50(9):1234-9.
17. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Hedman ÅK, Wilk JB, Morley MP, Chaffin MD. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nature communications. 2020;11(1):1-12.
18. Garnier S, Harakalova M, Weiss S, Mokry M, Regitz-Zagrosek V, Hengstenberg C, Cappola TP, Isnard R, Arbustini E, Cook SA. Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25. 1 and 22q11. 23. European Heart Journal. 2021;42(20):2000-11.

19. Zhou W, Kanai M, Wu K-HH, Rasheed H, Tsuo K, Hirbo JB, Wang Y, Bhattacharya A, Zhao H, Namba S. Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease. Cell Genomics. 2022;2(10).
20. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. International journal of epidemiology. 2015;44(2):512-25.
21. Burgess S, Zuber V, Valdes□Marquez E, Sun BB, Hopewell JC. Mendelian randomization with fine□mapped genetic data: choosing from large numbers of correlated instrumental variables. Genetic epidemiology. 2017;41(8):714-25.
22. Consortium U. The universal protein resource (UniProt) in 2010. Nucleic acids research. 2010;38(suppl_1):D142-D8.
23. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J, Gillespie M, Haw R. The reactome pathway knowledgebase. Nucleic acids research. 2020;48(D1):D498-D503.
24. She J, Guo M, Li H, Liu J, Liang X, Liu P, Zhou B, Liu S, Deng Y, Lou B. Targeting amino acids metabolic profile to identify novel metabolic characteristics in atrial fibrillation. Clinical science. 2018;132(19):2135-46.
25. Miyazawa K, Ito K, Ito M, Zou Z, Kubota M, Nomura S, Matsunaga H, Koyama S, Ieki H, Akiyama M. Cross-ancestry genome-wide analysis of atrial fibrillation unveils disease biology and enables cardioembolic risk prediction. Nature genetics. 2023;55(2):187-97.
26. Wang X, Huang T, Jia J. Proteome□Wide Mendelian Randomization Analysis Identified Potential Drug Targets for Atrial Fibrillation. Journal of the American Heart Association. 2023;12(16):e029003.
27. Ning Z, Huang Y, Lu H, Zhou Y, Tu T, Ouyang F, Liu Y, Liu Q. Novel Drug Targets for Atrial Fibrillation Identified Through Mendelian Randomization Analysis of the Blood Proteome. Cardiovascular Drugs and Therapy. 2023:1-8.
28. McCafferty EH, Scott LJ. Migalastat: a review in Fabry disease. Drugs. 2019;79:543-54.
29. Moroni A, Tondi L, Milani V, Pieroni M, Pieruzzi F, Bevilacqua F, Pasqualin G, Chow K, Pica S, Lombardi M. Left atrial remodeling in hypertrophic cardiomyopathy and Fabry disease: A CMR-based head-to-head comparison and outcome analysis. International Journal of Cardiology. 2023;393:131357.
30. Pogoda C, Brand S-M, Duning T, Schmidt-Pogoda A, Sindermann J, Lenders M, Brand E. Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease. Frontiers in Cardiovascular Medicine. 2023;10.
31. Li X, Ren X, Zhang Y, Ding L, Huo M, Li Q. Fabry disease: Mechanism and therapeutics strategies. Frontiers in Pharmacology. 2022;13:1025740.
32. Kukendrarajah K, Farmaki A-E, Lambiase PD, Schilling R, Finan C, Schmidt AF, Providencia R. Advancing drug development for atrial fibrillation by prioritising findings from human genetic association studies. EBioMedicine. 2024;105.
33. Komai K, Ito M, Nomura S, Shichino S, Katoh M, Yamada S, Ko T, Iizuka-Koga M, Nakatsukasa H, Yoshimura A. Single-cell analysis revealed the role of CD8+ effector T cells in preventing cardioprotective macrophage differentiation in the early phase of heart failure. Frontiers in Immunology. 2021;12:763647.
34. Sellak H, Franzini E, Hakim J, Pasquier C. Reactive oxygen species rapidly increase endothelial ICAM-1 ability to bind neutrophils without detectable upregulation. 1994.
35. Lillo R, Graziani F, Franceschi F, Iannaccone G, Massetti M, Olivotto I, Crea F, Liuzzo G. Inflammation across the spectrum of hypertrophic cardiac phenotypes. Heart Failure Reviews. 2023:1-11.
36. Rochette L, Dogon G, Zeller M, Cottin Y, Vergely C. GDF15 and cardiac cells: current concepts and new insights. International Journal of Molecular Sciences. 2021;22(16):8889.
37. Bradley J, Schelbert EB, Bonnett LJ, Lewis GA, Lagan J, Orsborne C, Brown PF, Black N, Naish JH, Williams SG. Growth differentiation factor-15 in patients with or at risk of heart failure but before first hospitalisation. Heart. 2023.
38. Antani J, Antani NJ, Nanivadekar A. Prazosin in chronic congestive heart failure due to ischemic heart disease. Clinical cardiology. 1991;14(6):495-500.

39. Colucci WS, Wynne J, Holman BL, Braunwald E. Long-term therapy of heart failure with prazosin: a randomized double blind trial. The American Journal of Cardiology. 1980;45(2):337-44.
40. Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, Tartaglia K, Chenot F, Moubayed S, Dierckx R. Acetazolamide in acute decompensated heart failure with volume overload. New England Journal of Medicine. 2022;387(13):1185-95.
41. Zhong H, Lin H, Pang Q, Zhuang J, Liu X, Li X, Liu J, Tang J. Macrophage ICAM-1 functions as a regulator of phagocytosis in LPS induced endotoxemia. Inflammation Research. 2021;70:193-203.
42. Wen L, Han Z. Identification and validation of xenobiotic metabolism-associated prognostic signature based on five genes to evaluate immune microenvironment in colon cancer. Journal of gastrointestinal oncology. 2021;12(6):2788.
43. Hubbard AK. Effects of xenobiotics on macrophage function: evaluation in vitro. Methods. 1999;19(1):8-16.
44. Katz DH, Robbins JM, Deng S, Tahir UA, Bick AG, Pampana A, Yu Z, Ngo D, Benson MD, Chen Z-Z. Proteomic profiling platforms head to head: leveraging genetics and clinical traits to compare aptamer-and antibody-based methods. Science Advances. 2022;8(33):eabm5164.
45. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, Gunnarsdottir K, Helgason A, Oddsson A, Halldorsson BV. Large-scale integration of the plasma proteome with genetics and disease. Nature Genetics. 2021;53(12):1712-21.
46. Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman ÅK, Schork A, Page K, Zhernakova DV, Wu Y, Peters J. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nature metabolism. 2020;2(10):1135-48.
47. Ahola-Olli AV, Würtz P, Havulinna AS, Aalto K, Pitkänen N, Lehtimäki T, Kähönen M, Lyytikäinen L-P, Raitoharju E, Seppälä I. Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors. The American Journal of Human Genetics. 2017;100(1):40-50.
48. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, O'Reilly PF, Amin N, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103-9.
49. Gudjonsson A, Gudmundsdottir V, Axelsson GT, Gudmundsson EF, Jonsson BG, Launer LJ, Lamb JR, Jennings LL, Aspelund T, Emilsson V. A genome-wide association study of serum proteins reveals shared loci with common diseases. Nature communications. 2022;13(1):1-13.
50. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E, Surendran P. Genomic atlas of the human plasma proteome. Nature. 2018;558(7708):73-9.
51. Gilly A, Park Y-C, Png G, Barysenka A, Fischer I, Bjørnland T, Southam L, Suveges D, Neumeyer S, Rayner NW. Whole-genome sequencing analysis of the cardiometabolic proteome. Nature communications. 2020;11(1):1-9.
52. Yang C, Farias FH, Ibanez L, Suhy A, Sadler B, Fernandez MV, Wang F, Bradley JL, Eiffert B, Bahena JA. Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nature neuroscience. 2021;24(9):1302-12.
53. Rücker G, Schwarzer G, Carpenter JR, Binder H, Schumacher M. Treatment-effect estimates adjusted for small-study effects via a limit meta-analysis. Biostatistics. 2011;12(1):122-42.
54. Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, Galver L, Kelley R, Karlsson A, Santos R. The druggable genome and support for target identification and validation in drug development. Science translational medicine. 2017;9(383):eaag1166.

Table 1. Positive controls and repurposing opportunities: prioritised proteins affected by approved drug compounds.

PROTEIN	UNIPROT ID	DRUGGABILITY*	METABOLITE CLASS(ES)*	NO. BREAKDOWN PRODUCTS*	BREAKDOWN PRODUCT EFFECT*	CARDIAC EFFECT*	OUTCOME	NO. DRUGS*	CARDIAC INDICATION AND/OR SIDE EFFECT*	CARDIAC INDICATION(S)	CARDIAC SIDE EFFECT(S)	DRUG NAME(S)
ACES	P22303	Drugged	Xenobiotics, Lipid	2	Mixed	1.09 (1.05; 1.13)	AF	23	Yes	Heart failure, Blood pressure disorders	See Appendix Table S7	See Appendix Table S7
ACES			Xenobiotics, Unclassified	2	Mixed	1.06 (1.04; 1.08)	HF					See Appendix Table S7
AT1B2	P14415	Drugged	Unclassified	1	Increasing	0.79 (0.72; 0.87)	HCM	9	Yes	See Appendix Table S7	Arrhythmias, Cardiac conduction disorder	Deslanoside, Digitoxin, Digoxin, Acetyldigitoxin, Istaroxime, Lanatoside c, Omeprazole, Lansoprazole, Pantoprazole
DPEP1	P16444	Drugged	Amino Acid, Unclassified, Peptide	5	Mixed	0.97 (0.96; 0.98)	AF	2	Yes	Endocarditis	See Appendix Table S7	Cilastatin sodium, Cilastatin
EGLN1	Q9GZT9	Drugged	Xenobiotics	1	Increasing	0.88 (0.84; 0.92)	AF	9	Yes	See Appendix Table S7	-	Vadadustat, Enarodustat, Molidustat, Roxadustat, Daprodustat, Oxygen, Ascorbic acid, Citric acid, Fumaric acid
ICAM1	P05362	Drugged	Xenobiotics, Unclassified	2	Mixed	1.10 (1.06; 1.14)	HCM	6	Yes	See Appendix Table S7	-	Enlimomab pegol, Bi-505, Enlimomab, Lovastatin, Lifitegrast, Dexamethasone
ICAM1			Xenobiotics	1	Decreasing	1.02 (1.01; 1.03)	HF					Enlimomab pegol, Bi-505, Enlimomab, Lovastatin, Lifitegrast, Dexamethasone
MANBA	O00462	Drugged	Lipid	1	Increasing	1.07 (1.06; 1.08)	AF	1	Yes	Fabry disease	-	Migalastat
MET	P08581	Drugged	Peptide	1	Increasing	0.92 (0.88; 0.95)	AF	98	Yes	See Appendix Table S7	Qt interval prolongation, Arrhythmias, Heart failure	See Appendix Table S7
NQO1	P15559	Drugged	Unclassified	1	Increasing	0.97 (0.96; 0.98)	HF	4	Yes	Thrombosis	-	Vatiquinone, Hydrogen peroxide, Dicumarol, Menadione
NQO2	P16083	Drugged	Amino Acid	1	Increasing	0.95 (0.93; 0.97)	HF	64	Yes	See Appendix Table S7	-	See Appendix Table S7
NTRK3	Q16288	Drugged	Unclassified	1	Increasing	0.73 (0.65; 0.83)	HCM	38	Yes	Pulmonary hypertension, Blood pressure disorders, Thrombosis	Qt interval prolongation, Heart failure, Blood pressure disorders	See Appendix Table S7
OLA1	Q9NTK5	Drugged	Unclassified	1	Increasing	0.81 (0.77; 0.85)	AF	47	Yes	See Appendix Table S7	-	See Appendix Table S7
RET	P07949	Drugged	Unclassified	1	Decreasing	0.97 (0.96; 0.98)	HF	75	Yes	See Appendix Table S7	Blood pressure disorders, Coronary heart disease	See Appendix Table S7
TEC	P42680	Drugged	Amino Acid	1	Increasing	0.87 (0.83; 0.90)	AF	61	Yes	See Appendix Table S7	-	See Appendix Table S7
TRY3	P35030	Drugged	Xenobiotics, Amino Acid	2	Mixed	0.92 (0.90; 0.94)	AF	15	Yes	See Appendix Table S7	-	See Appendix Table S7
TRYB1	Q15661	Drugged	Amino Acid, Unclassified	2	Increasing	1.02 (1.01; 1.03)	AF	1	Yes	Coronary heart disease, Heart failure, Blood pressure disorders	-	Arginine
UD11	P22309	Drugged	Peptide	1	Decreasing	2.87 (1.97; 4.17)	DCM	76	Yes	See Appendix Table S7	-	See Appendix Table S7
ADH1B	P00326	Drugged	Unclassified	1	Decreasing	1.14 (1.08; 1.20)	HF	2	No	-	-	Nitrefazole, Fomepizole
CAN2	P17655	Drugged	Unclassified	1	Decreasing	0.57 (0.46; 0.70)	HCM	2	No	-	-	Bortezomib, Carfilzomib
ENTP5	O75356	Drugged	Xenobiotics	1	Increasing	0.89 (0.86; 0.93)	AF	1	No	-	-	Anthralin
LYAM2	P16581	Drugged	Xenobiotics	1	Decreasing	1.25 (1.17; 1.33)	AF	4	No	-	-	Rivipansel, Cdp-850, Uproleselan, Bimosiamose

N.B. Characteristics of drugged prioritised proteins and urinary breakdown products associated with one or more cardiac disease(s). Cardiac effect estimates were obtained from *cis* Mendelian randomisation and are presented as odds ratios representing the effect of a one SD increase in protein levels, along with corresponding confidence intervals. The breakdown product effect indicates whether the breakdown product's effect on cardiac disease is risk-increasing or risk-decreasing, based on *cis* Mendelian randomisation. Druggability was determined based on ChEBML and the British National Formulary. Abbreviations: AF = atrial fibrillation, DCM = dilated cardiomyopathy, HCM = hypertrophic cardiomyopathy, HF = heart failure. More details can be found in Appendix Tables S6, S7.

Figure legends (main figures)

Figure 1. Flowchart of the main steps of this study

Abbreviations: AF = atrial fibrillation, DCM = dilated cardiomyopathy, HCM = hypertrophic cardiomyopathy, HF = heart failure.

Figure 2. A triangulation diagram illustrating an example of a triangulated association – with directional concordance – between a protein and its effects on urinary breakdown product values and cardiac disease

N.B. The plus symbol (in red) represents a positive association. The minus symbol (in blue) represents a negative association (a risk-decreasing effect). Directional concordance is achieved when the direction of effects aligns consistently, whether increasing or decreasing.

Figure 3. Urinary breakdown products associated with at least one cardiac outcome, presented per cardiac outcome

N.B. Presented p-values are corresponding to effect estimates obtained from Mendelian randomisation analyses leveraging genetic data on urinary breakdown products and cardiac diseases. Significant associations after multiplicity correction are indicated by a star, non-significant associations by a dot. The top row provides the number of drugged and druggable proteins, sourced from BNF and ChEMBL. Genetic associations with the cardiac outcomes were obtained from Nielsen *et al*. (60,620 AF cases)(16), from Shah *et al*. (47,309 HF cases)(17), from Garnier *et al*. (2,719 DCM cases)(18), and from Zhou *et al*. (2,993 HCM cases)(19). Genetic associations with urinary breakdown products are obtained from Schlosser et al.(n=1,627)(15). For more detailed information, please refer to the Methods section and **Appendix Table S2**.

Abbreviations: AF = atrial fibrillation, DCM = dilated cardiomyopathy, HCM = hypertrophic cardiomyopathy, HF = heart failure, MR = Mendelian randomisation.

Figure 4. Cardiac mRNA expression of directionally concordant proteins affecting cardiac disease presented as percentage of the total expression across all tissues.

N.B. Proteins are identified by their Uniprot label. Proteins displayed in bold font indicate that they are overexpressed in cardiac tissue compared to non-cardiac tissue. Data were sourced from the Human Protein Atlas; please refer to the Methods section for more details.

Figure 5. Forest plots of cardiac effects of drugged or druggable prioritised proteins, presented by cardiac disease

N.B. Point estimates are obtained from Mendelian randomisation analyses leveraging genetic data on plasma proteins and cardiac diseases. The metabolite classes of the breakdown products affected by the protein and concordantly associating with the cardiac diseases are indicated on the right y-axis. Genetic associations with the cardiac outcomes were sourced from Nielsen *et al*. (60,620 AF cases)(16), from Shah *et al*. (47,309 HF cases)(17), from Garnier *et al*. (2,719 DCM cases)(18), and from Zhou *et al*. (2,993 HCM cases)(19). For a more detailed description, please refer to the Methods section. Full numerical results can be found in **Appendix Tables S6, S7**.

Abbreviations: AF = atrial fibrillation, CI = confidence interval, DCM = dilated cardiomyopathy, HCM = hypertrophic cardiomyopathy, HF = heart failure, OR = odds ratio.

Figure 6. Forest plot of the cardiac effects of prioritised proteins associating with more than one cardiac outcome

N.B. Point estimates are obtained from Mendelian randomisation analyses leveraging genetic data on plasma proteins and cardiac diseases. The metabolite classes of the breakdown products affected by the protein and concordantly associating with each cardiac disease are indicated on the right y-axis. Genetic associations with the cardiac outcomes were sourced from Nielsen *et al*. (60,620 AF cases)(16), from Shah *et al*. (47,309 HF cases)(17), from Garnier *et al*. (2,719 DCM cases)(18), and from Zhou *et al*. (2,993 HCM cases)(19). For a more detailed description, please refer to the Methods section. Full numerical results can be found in **Appendix Table S6**.

Abbreviations: AF = atrial fibrillation, CI = confidence interval, DCM = dilated cardiomyopathy, HCM = hypertrophic cardiomyopathy, HF = heart failure, OR = odds ratio.


Step 1
Genome-wide MR
Urinary breakdown products
(n = 954)
Schlosser et al. (n = 1,627)
Cardiac outcomes:
AF, HF, DCM, HCM
AF: Nielsen et al. (60,620 cases)
HF: Shah et al. (47,309 cases)
DCM: Garnier et al. (2,719 cases)
HCM: Zhou et al. (2,993 cases)
Step 2
Cis-MR on urinary breakdown products
Unique urinary breakdown products associated with cardiac outcome
(n = 38)
Proteins
(n = 1,562 unique proteins)
deCODE (n = 35,559)
SCALLOP (n = 30,931)
Ahola-Olli et al. (n = 8,293)
Framingham (n = 6,861)
AGES-Reykjavik (n = 5,368)
INTERVAL (n = 3,301)
Gilly et al. (n = 1,328)
Yang et al. (n = 636)
Step 3
Cis-MR on cardiac outcomes
Cardiac outcomes:
AF, HF, DCM, HCM
Proteins associated with a cardiac urinary breakdown product
(n = 709)
Step 4
Prioritising on concordance in direction, cardiac expression and druggability
Unique proteins associated with both a cardiac urinary breakdown product and cardiac outcome
(n = 235)
Unique proteins with a directionally concordant association with both a urinary breakdown product and cardiac outcome, expressed in cardiac tissue
(n = 91)
Drugged proteins
(n = 20)
Druggable proteins
(n = 12)
Not yet druggable proteins
(n = 59)


Protein
+
−
Breakdown product
−
Outcome


Metabolite class:
Amino Acid
Carbohydrate
Lipid
Peptide
Xenobiotics
Unclassified
Drugged/druggable proteins
AF
HF
DCM
HCM
Cysteinylglycine disulfide
4-guanidinobutanoate
N-acetylcitrulline
Picolinate
Indoleacetylglutamine
N-acetylmethionine sulfoxide
1-methylhistamine
N-acetyl-3-methylhistidine
N-acetylputrescine
N-acetylarginine
N-acetylasparagine
N-acetyl-aspartyl-glutamate
N-acetylglucosamine/N-acetylgalactosamine
Nonenedioate
Glycochenodeoxycholate glucuronide
Glycocholenate sulfate
Prolylglycine
N-methylpipecolate
1-methylxanthine
3-hydroxyindolin-2-one sulfate
5-acetylamino-6-amino-3-methyluracil
5-acetylamino-6-formylamino-3-methyluracil
X - 24796
X - 12112
X - 19141
X - 24330
X - 23776
X - 15497
X - 23438
X - 18889
X - 24462
X - 24983
X - 12093
X - 21467
X - 13431
X - 12125
X - 24809
X - 12124
−8
−6
−4
−2
0
2
4
6
8
dir × −log10(p)


NAR3
TIG1
DNJA4
PLXA1
ACYP2
SPT20
GLO2
DS13A
CTGF
IBP7
IBP3
NQO2
TIMP3
EGLN1
ENOB
EMIL3
ECI2
LRIG1
SPRL1
MMAB
MICA
EVA1C
IC1
GLRX3
ICAM1
EMR2
OLA1
KLC1
SPON2
CAN2
FLRT2
TPSN
MANEA
CO4A
ADH1B
G6PE
MANBA
ERAP1
MAX
CATA
SWP70
HEXI1
EVL
FAAA
TEC
BPNT1
MET
ZA2G
CCL8
MICB
PDIA5
NTRK3
FCG2A
LYAM2
SHLB2
THG1
GNPTG
IFIT3
ACES
PLXB2
CC126
TNFL8
CYTF
NAGK
TRYB1
NQO1
NCTR3
PLA2R
HTAI2
MTHFS
LRC4B
SIGL7
C1QRF
ENTP5
AT1B2
MDGA1
MATN3
RET
CNTP2
SEM4A
FCRL4
ITIH1
TRY3
UD11
REG3G
KNG1
A1AT
DPEP1
CCL25
AMBP
APOC3
CYTD
SPA11
PZP
0
2
4
6
8
10
12
14
16
18
0
2
Percentage of total RNA expression in cardiac tissue


AF
DPEP1
NAGK
TRY3
ACES
GLO2
TRYB1
HEXI1
TEC
MANBA
MET
EGLN1
ENTP5
IBP3
LYAM2
MAX
OLA1
0.80
0.90
1.00
1.10
1.20
1.30
HF
ACES
APOC3
NQO2
ICAM1
ADH1B
CTGF
ERAP1
FCG2A
NQO1
RET
0.90
1.00
1.10
1.20
1.30
DCM
CATA
UD11
PLA2R
0.75
1.00
1.50
2.00
3.00
4.00
OR (95% CI)
HCM
ICAM1
PLA2R
AT1B2
CAN2
NTRK3
SIGL7
0.50
0.75
1.00
1.25
OR (95% CI)
Metabolite class:
Amino Acid
Lipid
Peptide
Xenobiotics
Unclassified


MICB
PLXB2
PLXA1
MATN3
ACES
CYTF
ICAM1
EVA1C
PLA2R
ACYP2
GNPTG
AF
HF
HCM
DCM
0.25
0.50
0.75
1.00
1.50
OR (95% CI)
Metabolite class:
Amino Acid
Lipid
Xenobiotics
Unclassified